Fig. 5. Wedelolactone decreases EZH2-dependent trimethylation of H3K27 on the promoter region of FOXO1. (A) Chromatin immu-noprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) analysis of H3K27me3 enrichment in FOXO1 promoter after wedelolactone intervention in both human iPSC-derived MSCs and 293T cells. (B) Reverse transcription (RT)-qPCR analysis of FOXO1 in human iPSC-derived MSCs after FOXO1 inhibitor (GSK126) intervention. (C) Western blotting analysis of FOXO1 in human iPSC-derived MSCs after FOXO1 inhibitor (GSK126) intervention. (D) ChIP-qPCR analysis of EZH2 occupancy in FOXO1 promoter in both human iPSC-derived MSCs and 293T cells. (E) Western blotting analysis of FOXO1 in human iPSC-derived MSCs after EZH2 overexpression. (F) RT-qPCR analysis of FOXO1 in human iPSC-derived MSCs after EZH2 knockdown. (G) Western blotting analysis of FOXO1 in human iPSC-derived MSCs after EZH2 knockdown. (H) RT-qPCR analysis of FOXO1 in human iPSC-derived MSCs induced with wedelolactone after EZH2 knockdown.

International Journal of Stem Cells 2023;16:326-41 https://doi.org/10.15283/ijsc22046

© 2023 International Journal of Stem Cells